Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2014; 5(5): 908-920
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.908
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.908
Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets
Shiro Koizume, Yohei Miyagi, Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama 241-8515, Japan
Author contributions: Koizume S conceived and wrote the manuscript; Miyagi Y provided constructive comments; Koizume S and Miyagi Y approved the final version of the manuscript.
Correspondence to: Dr. Shiro Koizume, Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao Asahi-ku, Yokohama 241-8515, Japan. skoizume@gancen.asahi.yokohama.jp
Telephone: +81-45-520-2222
Received: January 10, 2014
Revised: July 22, 2014
Accepted: July 27, 2014
Published online: December 10, 2014
Processing time: 335 Days and 5 Hours
Revised: July 22, 2014
Accepted: July 27, 2014
Published online: December 10, 2014
Processing time: 335 Days and 5 Hours
Core Tip
Core tip: Breast cancer is a worldwide problem. Difficulties with treating the disease and its recurrence persist due, in part, to a lack of therapeutic molecular targets. Blood coagulation factor VII (fVII) is generally produced in the liver. Tissue factor (TF), the cellular receptor for fVII, is an integral membrane protein that plays key roles in the extrinsic coagulation cascade. Formation of the TF-fVII complex causes contributes to the malignant phenotype of breast cancer cells. In this review, we summarize the breast cancer biology associated with the TF-fVII pathway. Further, we will discuss how these mechanisms can be targeted as therapeutics for this aggressive disease.